Skip to main content
. 2022 May 16;39(9):110904. doi: 10.1016/j.celrep.2022.110904

Figure 1.

Figure 1

Anti-spike IgG levels in convalescent donors correlate with COVID-19 severity

(A) Anti-spike IgG titers in SARS-CoV-2 convalescent (CoV-2+) and naive (CoV-2−) donors, as quantified by ELISA (n = 28 and 20, respectively).

(B) Levels of anti-spike IgG in convalescent (CoV-2+) donors, as quantified by ELISA. Red line represents 3-fold above the mean anti-spike levels of naive (CoV-2−) donors, as quantified by ELISA.

(C) Comparison of ELISA-based anti-spike IgG titers versus CoV-2+ composite severity scores.

(D–F) Levels of anti-spike IgG in naive (CoV-2−) and CoV-2+ donors, as quantified using a cell-based assay (CBA).

(D) Levels of anti-spike IgG titers in CoV-2− and CoV-2+ donors.

(E) Levels of anti-spike titers in CoV-2+ donors, as quantified by CBA.

(F) Comparison of CBA anti-spike IgG titers versus CoV-2+ composite severity scores. The SEMs of N = 3 experiments are shown.